Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
Centessa (NASDAQ:CNTA) filed a Form 4 showing that President, Orexin Program Mario Alberto Accardi exercised options for 15,000 ordinary shares at $3.85 and immediately sold the same 15,000 shares at $14.00 on 06/24/2025 under a Rule 10b5-1 plan.
The transaction generated roughly $210 k in gross proceeds and reduced his direct holdings by 6.5% to 216,485 shares; he still holds 15,300 vested options. Because the sale exceeds 5% of his prior stake, it meets materiality thresholds for insider activity that investors track for sentiment shifts.
Centessa Pharmaceuticals (NASDAQ: CNTA) submitted a Form 144 notice covering the proposed sale of 10,000 common shares—approximately $140,000 in aggregate market value—through UBS Financial Services on or around 26 June 2025. The filing lists 133,618,774 shares outstanding, so the planned sale represents less than 0.01 % of the float.
The same account holder reported three earlier open‐market sales during the past three months: 10,000 shares on 25 March 2025 for $163,386, 11,742 shares on 25 April 2025 for $159,857, and 10,000 shares on 27 May 2025 for $128,225. Combined with the new notice, gross proceeds from the four transactions total roughly $591,000. No additional financial statements, risk factors, or business updates were provided in this routine disclosure.
A Form 144 filing from Centessa Pharmaceuticals indicates a proposed sale of 15,000 shares of common stock through UBS Financial Services. The shares have an aggregate market value of $210,000, with the sale planned for June 24, 2025 on the Nasdaq exchange.
The securities were acquired through the exercise of stock options from the issuer on June 24, 2025, with payment made in cash. The total outstanding shares of the company are 133,618,774.
Key details:
- Share price implied by filing: $14.00 per share
- No other securities sales reported by the seller in the past 3 months
- Transaction represents approximately 0.011% of total outstanding shares
Director Arjun Goyal of Centessa Pharmaceuticals was granted 40,000 stock options on June 20, 2025. The options have the following key terms:
- Exercise price set at $12.43 per share
- Expiration date of June 20, 2035
- Vesting occurs at earlier of: - First anniversary of grant date - Next annual shareholder meeting
- Options convert to ordinary shares (which may be represented as American Depositary Shares)
- Vesting conditional on continued service as director
This Form 4 filing, signed by attorney-in-fact Iqbal Hussain, represents a standard director compensation equity grant, suggesting continued commitment to aligning director interests with shareholders through long-term equity incentives.
Form 4 filing reveals that Mary Lynne Hedley, Director at Centessa Pharmaceuticals, was granted 40,000 share options on June 20, 2025. The stock options have an exercise price of $12.43 per share and will expire on June 20, 2035.
Key details of the option grant:
- Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) next annual shareholder meeting
- Vesting is contingent on continued service as director
- Options are convertible into ordinary shares, which may be represented as American Depositary Shares (1:1 ratio)
- Direct ownership form reported
This grant appears to be part of the company's director compensation program. No other securities transactions were reported in this filing.
Form 4 filing reveals that Samarth Kulkarni, Director at Centessa Pharmaceuticals, received a stock option grant on June 20, 2025. Key details:
- Granted 40,000 stock options to purchase ordinary shares at an exercise price of $12.43 per share
- Options will vest in full at the earlier of: - First anniversary of grant date - Next annual shareholder meeting
- Options expire on June 20, 2035
- Vesting conditional on continued service as director
- Ordinary shares may be represented by American Depositary Shares (ADS), with each ADS representing one ordinary share
This equity compensation grant aligns with standard director compensation practices and aims to align the director's interests with shareholders. The filing was signed by Iqbal Hussain as attorney-in-fact on June 24, 2025.
Centessa Pharmaceuticals director Carol Stuckley received a stock option grant on June 20, 2025. The derivative securities transaction details include:
- Granted 40,000 share options to purchase ordinary shares
- Exercise price set at $12.43 per share
- Options expire on June 20, 2035
- Vesting occurs at earlier of:
- First anniversary of grant date
- Next annual shareholder meeting
The options are subject to continued service as director through the vesting date. Each ordinary share may be represented by one American Depositary Share (ADS). The transaction was reported via Form 4 filing with attorney-in-fact signature dated June 24, 2025.
Centessa Pharmaceuticals plc (CNTA) – Form 4 insider filing
Director Brett I. W. Zbar reported the grant of an option to acquire 40,000 ordinary shares of Centessa Pharmaceuticals on 20 June 2025 at an exercise price of $12.43 per share. The instrument is classified as a “Share Option (right to buy)” and is held directly.
The option vests in full on the earlier of (i) the first anniversary of 20 June 2025 or (ii) the Company’s next annual meeting of shareholders, subject to Dr. Zbar’s continued service as director. The option carries a 10-year term with an expiration date of 20 June 2035. Following the grant, Dr. Zbar reports beneficial ownership of 40,000 derivative securities and no change to non-derivative share ownership was disclosed.
The filing notes that the option is held by Dr. Zbar solely for the benefit of General Atlantic Service Company, L.P.; he disclaims beneficial ownership except to the extent of any pecuniary interest.
No open-market purchases or sales of CNTA ordinary shares or ADSs were reported, and the filing does not indicate transactions made under a Rule 10b5-1 plan.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025. The estimated aggregate market value is $168,218.40, implying a per-share price of roughly $14.02. The filing states that 133,618,774 shares are outstanding, meaning the planned sale represents less than 0.01 % of total shares. The seller acquired the shares the same day via a cash-settled stock-option exercise.
The insider previously sold a combined 6,000 shares over the past three months for total proceeds of $84,012.01. No additional operational or financial data were disclosed, and the signatory affirms awareness of no undisclosed material adverse information. Given the modest size relative to the float and the routine nature of Form 144 notices, the event is unlikely to materially affect Centessa’s fundamentals or valuation.